

Table S5. Summary of median days on first-, second-, and third-line therapy; patients with psoriatic arthritis who initiated and discontinued new therapy during the registry

	<u>Ustekinumab</u>	<u>Infliximab</u>	<u>Adalimumab</u>	<u>Etanercept</u>
Patients with PsA	186	87	139	48
First-Line Therapy				
All Patients, N	41	20	33	25
Days on Therapy	598 (435 - 887)	402 (256 - 948)	698 (393 - 845)	794 (246 - 1032)
Discontinued, N	7	3	6	7
Days on therapy	361 (198 - 600)	176 (99 - 423)	299 (69 - 400)	193 (131 - 246)
Second-Line Therapy				
All Patients, N	63	18	84	27
Days on Therapy	677 (316 - 893)	390 (153 - 616)	403 (148 - 646)	443 (168 - 823)
Discontinued, N	13	8	28	10
Days on Therapy	200 (158 - 308)	177 (119 - 414)	143 (89 - 345)	262 (77 - 343)
Third-Line Therapy				
All Patients, N	82	19	22	18
Days on Therapy	581 (358 - 963)	392 (264 - 595)	302 (90 - 553)	145 (50 - 501)
Discontinued, N	20	6	8	9
Days on Therapy	237 (168 - 483)	261 (158 - 595)	65 (29 - 133)	50 (17 - 113)

Days on therapy are presented as median (interquartile range). PsA, psoriatic arthritis.